Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 309

The DOI matches its Crossref record; 42 of the 42 references it cites were found in a registry or an index.

Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders

·2016·Obstetrics & Gynecology

Abstract

Prenatal genetic diagnostic testing is intended to determine, with as much certainty as possible, whether a specific genetic disorder or condition is present in the fetus. In contrast, prenatal genetic screening is designed to assess whether a patient is at increased risk of having a fetus affected by a genetic disorder. Originally, prenatal genetic testing focused primarily on Down syndrome (trisomy 21), but now it is able to detect a broad range of genetic disorders. Although it is necessary to perform amniocentesis or chorionic villus sampling (CVS) to definitively diagnose most genetic disorders, in some circumstances, fetal imaging with ultrasonography, echocardiography, or magnetic resonance imaging may be diagnostic of a particular structural fetal abnormality that is suggestive of an underlying genetic condition.The objective of prenatal genetic testing is to detect health problems that could affect the woman, fetus, or newborn and provide the patient and her obstetrician-gynecologist or other obstetric care provider with enough information to allow a fully informed decision about pregnancy management. Prenatal genetic testing cannot identify all abnormalities or problems in a fetus, and any testing should be focused on the individual patient's risks, reproductive goals, and preferences. It is important that patients understand the benefits and limitations of all prenatal screening and diagnostic testing, including the conditions for which tests are available and the conditions that will not be detected by testing. It also is important that patients realize that there is a broad range of clinical presentations, or phenotypes, for many genetic disorders and that results of genetic testing cannot predict all outcomes. Prenatal genetic testing has many benefits, including reassuring patients when results are normal, identifying disorders for which prenatal treatment may provide benefit, optimizing neonatal outcomes by ensuring the appropriate location for delivery and the necessary personnel to care for affected infants, and allowing the opportunity for pregnancy termination.The purpose of this Practice Bulletin is to review the current status of prenatal genetic diagnostic testing and the evidence supporting its use. For information regarding screening for fetal aneuploidy, refer to Practice Bulletin No. 163, Screening for Fetal Aneuploidy.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1097/aog.0000000000001405

Cites

42 of 42 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 42 references

Research works printed but not linked: 29

  1. Tepperberg, 2001, Prenatal diagnosis using interphase fluorescence in situ hybridization (FISH): 2-year multi-center retrospective study and review of the literature, Prenat Diagn, 21, 293, 10.1002/pd.57 · doi:10.1002/pd.57
  2. Bryndorf, 2000, Rapid prenatal diagnosis of chromosome aneuploidies by interphase fluorescence in situ hybridization: a one-year clinical experience with high-risk and urgent fetal and postnatal samples, Acta Obstet Gynecol Scand, 79, 8
  3. 2000, I. Technical considerations. Test and Technology Transfer Committee, American College of Medical Genetics., Genet Med, 2, 356
  4. 2013, Committee Opinion No. 581. American College of Obstetricians and Gynecologists., Obstet Gynecol, 122, 1374
  5. Zhu, 2014, Diagnostic accuracy of non-invasive fetal RhD genotyping using cell-free fetal DNA: a meta analysis, J Matern Fetal Neonatal Med, 27, 1839, 10.3109/14767058.2014.882306 · doi:10.3109/14767058.2014.882306
  6. Kuliev, May 21, 1994, Chorionic villus sampling safety. Report of World Health Organization/EURO meeting in association with the Seventh International Conference on Early Prenatal Diagnosis of Genetic Diseases, Tel-Aviv, Israel, Am J Obstet Gynecol, 1996, 807
  7. 1998, The Canadian Early and Mid-trimester Amniocentesis Trial (CEMAT) Group., Lancet, 351, 242
  8. Cambiaghi, 1998, Skin dimpling as a consequence of amniocentesis, J Am Acad Dermatol, 39, 888, 10.1016/S0190-9622(98)70373-1 · doi:10.1016/s0190-9622(98)70373-1
  9. Winsor, 1999, Cytogenetic aspects of the Canadian early and mid-trimester amniotic fluid trial (CEMAT), Prenat Diagn, 19, 620, 10.1002/(SICI)1097-0223(199907)19:7<620::AID-PD599>3.0.CO;2-E · doi:10.1002/(sici)1097-0223(199907)19:7<620::aid-pd599>3.0.co;2-e
  10. Romero, 1985, Sonographically monitored amniocentesis to decrease intraoperative complications, Obstet Gynecol, 65, 426
  11. Leschot, 1985, Risks of midtrimester amniocentesis; assessment in 3000 pregnancies, Br J Obstet Gynaecol, 92, 804, 10.1111/j.1471-0528.1985.tb03049.x · doi:10.1111/j.1471-0528.1985.tb03049.x
  12. Silver, 1990, An evaluation of the chorionic villus sampling learning curve, Am J Obstet Gynecol, 163, 917, 10.1016/0002-9378(90)91096-U · doi:10.1016/0002-9378(90)91096-u
  13. Wijnberger, 2000, Learning in medicine: chorionic villus sampling, Prenat Diagn, 20, 241, 10.1002/(SICI)1097-0223(200003)20:3<241::AID-PD793>3.0.CO;2-X · doi:10.1002/(sici)1097-0223(200003)20:3<241::aid-pd793>3.0.co;2-x
  14. Bovicelli, 1982, Reproduction in Down syndrome, Obstet Gynecol, 59, 13S
  15. 2014, Technology Assessment No. 11. American College of Obstetricians and Gynecologists., Obstet Gynecol, 123, 394
  16. Arth, 2015, Supplement use and other characteristics among pregnant women with a previous pregnancy affected by a neural tube defect - United States, 1997-2009. Centers for Disease Control and Prevention, MMWR Morb Mortal Wkly Rep, 64, 6
  17. Pyott, 2011, Recurrence of perinatal lethal osteogenesis imperfecta in sibships: parsing the risk between parental mosaicism for dominant mutations and autosomal recessive inheritance, Genet Med, 13, 125, 10.1097/GIM.0b013e318202e0f6 · doi:10.1097/gim.0b013e318202e0f6
  18. Uehara, 1999, Risk of recurrence of fetal chromosomal aberrations: analysis of trisomy 21, trisomy 18, trisomy 13, and 45,X in 1,076 Japanese mothers, J Obstet Gynaecol Res, 25, 373, 10.1111/j.1447-0756.1999.tb01180.x · doi:10.1111/j.1447-0756.1999.tb01180.x
  19. Williamson, 1987, Abnormal pregnancy sonogram: selective indication for fetal karyotype, Obstet Gynecol, 69, 15
  20. 2016, Practice Bulletin No. 163. American College of Obstetricians and Gynecologists., Obstet Gynecol, 127, e123
  21. Ko, 1994, Amniocentesis in mothers who are hepatitis B virus carriers does not expose the infant to an increased risk of hepatitis B virus infection, Arch Gynecol Obstet, 255, 25, 10.1007/BF02390671 · doi:10.1007/bf02390671
  22. Coll, 2006, Prenatal diagnosis in human immunodeficiency virus-infected women: a new screening program for chromosomal anomalies, Am J Obstet Gynecol, 194, 192, 10.1016/j.ajog.2005.06.045 · doi:10.1016/j.ajog.2005.06.045
  23. Meyers, 1997, Aneuploidy in twin gestations: when is maternal age advanced?, Obstet Gynecol, 89, 248, 10.1016/S0029-7844(96)00424-3 · doi:10.1016/s0029-7844(96)00424-3
  24. Boyle, 2014, Prevalence and risk of Down syndrome in monozygotic and dizygotic multiple pregnancies in Europe: implications for prenatal screening, BJOG, 121, 809, 10.1111/1471-0528.12574 · doi:10.1111/1471-0528.12574
  25. Wapner, 1993, Prenatal diagnosis in twin gestations: a comparison between second-trimester amniocentesis and first-trimester chorionic villus sampling, Obstet Gynecol, 82, 49
  26. Goldberg, 1997, Incidence and outcome of chromosomal mosaicism found at the time of chorionic villus sampling, Am J Obstet Gynecol, 176, 1349, 10.1016/S0002-9378(97)70356-9 · doi:10.1016/s0002-9378(97)70356-9
  27. Hahnemann, 1997, European collaborative research on mosaicism in CVS (EUCROMIC)—fetal and extrafetal cell lineages in 192 gestations with CVS mosaicism involving single autosomal trisomy, Am J Med Genet, 70, 179, 10.1002/(SICI)1096-8628(19970516)70:2<179::AID-AJMG15>3.0.CO;2-G · doi:10.1002/(sici)1096-8628(19970516)70:2<179::aid-ajmg15>3.0.co;2-g
  28. Hsu, 1996, Incidence and significance of chromosome mosaicism involving an autosomal structural abnormality diagnosed prenatally through amniocentesis: a collaborative study, Prenat Diagn, 16, 1, 10.1002/(SICI)1097-0223(199601)16:1<1::AID-PD816>3.0.CO;2-W · doi:10.1002/(sici)1097-0223(199601)16:1<1::aid-pd816>3.0.co;2-w
  29. Clark, 1989, Prenatal diagnosis for couples who would not consider abortion, Obstet Gynecol, 73, 1035

Cited by

See all 309

Metadata

Venue
Obstetrics & Gynecology
Published
2016-05
Volume
127
Issue
5
Pages
e108-e122
ISSN
0029-7844 (ISSN-L)
OpenAlex
W4240064556
Cited by
309
References
42
FWCI
28.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. https://app.cochat.ai/papers/10.1097/aog.0000000000001405
The paper
Practice Bulletin No. 162: Prenatal Diagnostic Testing for Genetic Disorders. (2016). Obstetrics & Gynecology. https://doi.org/10.1097/aog.0000000000001405

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.